<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185468</url>
  </required_header>
  <id_info>
    <org_study_id>GIMI-IRB-17004</org_study_id>
    <nct_id>NCT03185468</nct_id>
  </id_info>
  <brief_title>Intervention of Bladder Cancer by CAR-T</brief_title>
  <official_title>Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Geno-Immune Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Geno-Immune Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II and multicenter study designed to evaluate the efficacy and safety of
      4SCAR-T cells in participants with locally advanced or metastatic urothelial bladder cancer
      (UBC) who have no further treatment available.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival rate after receiving 4SCART infusion</measure>
    <time_frame>1 year</time_frame>
    <description>to determine the efficacy of 4SCAR T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Using CTCAE 4 standard to evaluate the level of adverse events after receiving 4SCART infusion</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate the level of adverse events with CTCAE 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The expansion and persistence of 4SCAR T cells</measure>
    <time_frame>1 year</time_frame>
    <description>The investigators will monitor the expansion and functional persistence of 4SCAR T cells in the peripheral blood of patients and the correlation with antitumor effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune responses after infusions</measure>
    <time_frame>3 months</time_frame>
    <description>assessment of cytokine profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Urothelial Carcinoma Bladder</condition>
  <arm_group>
    <arm_group_label>4SCAR-PSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4SCAR-FRa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>4SCAR-PSMA</intervention_name>
    <description>PSMA-specific 4th Generation CART</description>
    <arm_group_label>4SCAR-PSMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>4SCAR-FRa</intervention_name>
    <description>FRa-specific 4th Generation CART</description>
    <arm_group_label>4SCAR-FRa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically documented locally advanced or metastatic UBC
             (including renal pelvis, ureters, urinary bladder, and urethra)

          2. Representative tumor specimens as specified by the protocol

          3. Adequate hematologic and end organ function

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          5. Life expectancy greater than or equal to (&gt;/=) 12 weeks

          6. Measurable disease, as defined by RECIST v1.1

        Exclusion Criteria:

          1. Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment

          2. Treatment with any other investigational agent or participation in another clinical
             trial with therapeutic intent within 28 days prior to enrollment

          3. Active or untreated central nervous system (CNS) metastases as determined by computed
             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and
             prior radiographic assessments

          4. Leptomeningeal disease

          5. Malignancies other than UBC within 5 years prior to Cycle 1, Day 1

          6. Pregnant and lactating women

          7. Significant cardiovascular disease

          8. Severe infections within 4 weeks prior to infusion

          9. Major surgical procedure other than for diagnosis within 4 weeks

         10. History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy
             to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the
             atezolizumab formulation

         11. History of autoimmune disease

         12. Prior allogeneic stem cell or solid organ transplant

         13. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan

         14. Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or
             hepatitis C or tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lung-Ji Chang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Geno-Immune Medical Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lung-Ji Chang, PhD</last_name>
    <phone>86-13671121909</phone>
    <email>c@szgimi.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aifa Tang, PhD</last_name>
    <email>tangaifa2004@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenzhen Second People Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Gongdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AiFa Tang, Ph. D</last_name>
      <email>tangaifa2004@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Geno-immune Medical Institute</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lung-Ji Chang, PhD</last_name>
      <phone>86-13671121909</phone>
      <email>c@szgimi.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2017</study_first_submitted>
  <study_first_submitted_qc>June 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen Geno-Immune Medical Institute</investigator_affiliation>
    <investigator_full_name>Lung-Ji Chang</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

